ERVW-1 and multiple sclerosis: Satralizumab and inebilizumab have been recently approved in the treatment of NMOSD [108,109,110], while temelimab, an IgG4 monoclonal antibody targeting the endogenous retroviral envelope protein HERV-W-Env, is currently under development as a disease-modifying therapy for multiple sclerosis [111,112,113].